Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795224B2 · kind B2 · utility
1Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 18, 2022 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | Mar 18, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/7051
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ε. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ε.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.